Stroke,
Workplace,
INE,
Cardiovascular disease,
Splenic infarction,
Peaceful transition of power,
CVD,
Amarin,
Professional corporation,
Committee,
GDP,
Patient,
Risk,
Instituto Nacional de Estadística (Spain),
Growth,
Death,
Disease,
Health insurance,
Pharmaceutical industry,
Health DUBLIN, Ireland and BRIDGEWATER, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announces that following the most recent meeting of the Spanish Drug Pricing Committee (Comisión Interministerial de Precios de los Medicamentos) on July 24, 2023, the Committee is recommending the national reimbursement of VAZKEPA® (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in patients with high cardiovascular risk1.
Key Points:
- “Cardiovascular disease is still one of Spain’s leading causes of death and patients with this disease need access to new treatments that can reduce their risk of having another event.
- According to data published by the Spanish National Statistics Institute (INE), in 2020 around 200,000 people died as a result of cardiovascular disease (CVD), making it the leading cause of death for the Spanish population as a whole, ahead of cancer2.
- In addition, more than 457,000 new cases are diagnosed each year in Spain.
- “Our team in Spain will now be laser-focused on supporting efforts to reach healthcare professionals and drive awareness and adoption of this important new treatment for patients.
DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Today the Board of Directors of Amarin Corporation plc (NASDAQ: AMRN) announced details regarding the compensation program for the Company’s new President and Chief Executive Officer (CEO), Patrick Holt, who was appointed to the role on July 18, 2023.
Key Points:
- DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Today the Board of Directors of Amarin Corporation plc (NASDAQ: AMRN) announced details regarding the compensation program for the Company’s new President and Chief Executive Officer (CEO), Patrick Holt, who was appointed to the role on July 18, 2023.
- The realizable value is at-risk equity and directly dependent upon the sustained performance of the Company’s share price and, thus, aligned with the interest of shareholders.
- Mr. Holt has also agreed to purchase $300,000 worth of Amarin shares in the open market using personal funds.
- Holt’s compensation addresses the long-standing frustration of shareholders who want executive compensation directly tied to the creation of shareholder value,” said Odysseas Kostas, M.D., the Chairman of the Board.
Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
Key Points:
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
- We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
Pressure,
Telephone,
EDT,
Science,
Professional corporation,
IPE,
International Partnership on Avian and Pandemic Influenza,
Patient,
MENA,
Conference,
Pharmaceutical industry,
Renewable energy,
Amarin -- Company to Host Conference Call Today at 5:00 p.m. EDT --
Key Points:
- Over the last several months, the new Amarin Board of Directors and senior management team have conducted a comprehensive review of the business.
- Amarin continues to generate revenue in the U.S. and maintains a strong cash position.
- However, the restructuring announced today reflects the need for a thoughtful and significant change in strategy given the Company’s size, resources and challenging operating environment.
- The Company expects these actions will reduce operating costs by approximately $40 million annually.
Vaccine,
Interim,
Allergan,
Sale,
Amarin,
Professional corporation,
Patient,
Physician,
Management,
Cordis,
Merck DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company’s Board of Directors has appointed Patrick Holt as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately.
Key Points:
- DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company’s Board of Directors has appointed Patrick Holt as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately.
- Aaron Berg, who served as Interim President and CEO since April 2023, will remain with the Company in a senior leadership role.
- Mr. Holt brings more than 25 years of leadership in the life sciences industry and significant international operating experience.
- Mr. Holt previously held a variety of senior executive positions across biopharmaceuticals and vaccines at Allergan and Merck.
China Biologic Products,
Intellectual property,
Research and development,
Diabetes,
Dyslipidemia,
CV,
Marketing,
Saudi Food and Drug Authority,
Cardiovascular disease,
SHC,
KSA,
SFDA,
TG,
Amarin,
Professional corporation,
IPE,
Development,
Capsule,
Publication,
Patient,
Risk,
NHC,
Kingdom,
United Arab Emirates,
Pharmaceutical industry DUBLIN, Ireland and BRIDGEWATER, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and its commercialization partner Biologix FZco, a company based in the United Arab Emirates and a pioneer in the distribution of pharmaceutical and biological products in the Middle East and North Africa, today announced that the Kingdom of Saudi Arabia’s (KSA) Saudi Food and Drug Authority (SFDA) has approved a new indication and label expansion for VASCEPA® (icosapent ethyl) capsules. VASCEPA is now the first and only drug approved by SFDA as an adjunct to statin therapy in adult patients with elevated triglycerides (TG) levels (≥150 mg/dL) who are at high-risk of cardiovascular (CV) events due to established cardiovascular disease or diabetes mellitus and at least one other risk factor for cardiovascular disease.
Key Points:
- VASCEPA is now the first and only drug approved by SFDA as an adjunct to statin therapy in adult patients with elevated triglycerides (TG) levels (≥150 mg/dL) who are at high-risk of cardiovascular (CV) events due to established cardiovascular disease or diabetes mellitus and at least one other risk factor for cardiovascular disease.
- “We are excited that patients in KSA will now have the opportunity to benefit from the proven cardiovascular risk reduction with VASCEPA following the approval by the SFDA,” said Steven Ketchum, PhD., President, Research & Development and Chief Scientific Officer, Amarin.
- “Today’s approval also marks an important step in our strategy to expand the global footprint where VASCEPA/VAZKEPA is indicated for cardiovascular risk reduction, built from the results seen in the REDUCE-IT outcomes trial.
- Amarin is responsible for providing regulatory assistance, supply and maintaining intellectual property in the region.
Moyamoya disease,
Partnership,
Research and development,
Diet,
Hypertriglyceridemia,
CVRR,
Stroke,
Cardiovascular disease,
Ageing,
Drug,
CVD,
Amarin,
Professional corporation,
Development,
Death,
Patient,
World Heart Federation,
Growth,
NRDL,
NMPA,
Disease,
Pharmaceutical industry DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that its commercial partner in China, EddingPharm (EDDING), has received regulatory approval for VASCEPA® (icosapent ethyl) from China’s National Medical Products Administration (NMPA). NMPA granted approval for VASCEPA as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL).
Key Points:
- DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that its commercial partner in China, EddingPharm (EDDING), has received regulatory approval for VASCEPA® (icosapent ethyl) from China’s National Medical Products Administration (NMPA).
- NMPA granted approval for VASCEPA as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL).
- Following regulatory approval, EDDING is now focusing on National Reimbursement Drug Listing (NRDL) and preparing for commercial launch in China, expected by year-end, as well as on advancing regulatory submission and review for an additional indication in cardiovascular risk reduction (CVRR).
- Following the NMPA approval for this indication, Amarin is now entitled to receive a regulatory milestone payment of $5 million.
DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Aaron Berg, Amarin’s Interim President and Chief Executive Officer and Tom Reilly, Amarin’s Chief Financial Officer, will present at two upcoming investor conferences:
Key Points:
- DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Aaron Berg, Amarin’s Interim President and Chief Executive Officer and Tom Reilly, Amarin’s Chief Financial Officer, will present at two upcoming investor conferences:
Jefferies Healthcare Conference (June 7-9, 2023; New York, New York)
Goldman Sachs 44th Annual Global Healthcare Conference (June 12-15, 2023; Dana Point, California)
CT,
Plaque,
Myocardial infarction,
Diabetes,
MB,
Macrophage,
NIRF,
Triglyceride,
Cardiovascular disease,
Radiology,
CAD,
CTA,
Research,
Loyola University,
IVUS,
CH.B,
Atherosclerosis,
Amarin,
Professional corporation,
European Heart Journal: Cardiovascular Imaging,
Ethyl eicosapentaenoic acid,
Animal,
Computed tomography angiography,
Patient,
European Heart Journal,
Molecular imaging,
American Heart,
Pharmaceutical industry,
Medical imaging,
MD DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted new data describing the benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) on coronary physiology, which was published in the European Heart Journal - Cardiovascular Imaging, and plaque progression, which was presented at the American Heart Association’s Vascular Discovery 2023 meeting in Boston, MA, May 10-13.
Key Points:
- EVAPORATE demonstrated that in statin-treated patients, VASCEPA/VAZKEPA significantly reduced plaque burden measured by serial coronary computed tomography angiography (CTA) compared with placebo.
- VASCEPA/VAZKEPA improved mean distal segment FFRCT at 9- and 18-months follow-up compared with placebo (P = 0.02, P = 0.03 respectively).
- “These new findings from two different studies provide important mechanistic information about VASCEPA/VAZKEPA and further elucidate its value in reducing cardiovascular events in at-risk patients,” said Nabil Abadir, MB.
- We are proud to add to the body of research that further demonstrates the benefit of VASCEPA/VAZKEPA."
England and Wales,
Partnership,
Operational definition,
Telephone,
HTA,
GAAP,
EDT,
Amarin,
Forecasting,
Professional corporation,
IPE,
Patient,
Investment,
Research,
Conference,
Health technology assessment,
Bank,
Pharmaceutical industry,
Airline,
Cryptocurrency -- Company to Host Conference Call Today at 8:00 a.m. EDT --
Key Points:
- To date in the U.K., Amarin is working to secure VAZKEPA patient access through local formulary negotiations, and we expect those negotiations will continue to progress throughout 2023.
- In the first quarter of 2023, Amarin secured regulatory approval for VAZKEPA in New Zealand and Israel.
- During the three months ended March 31, 2023, Amarin amended a supplier agreement resulting in a charge of $12.3 million.
- The company has provided these non-GAAP financial measures in addition to GAAP financial results because it believes that these non-GAAP adjusted financial measures provide investors with a better understanding of the company’s historical results from its core business operations.
